



## DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville, MD 20857

December 17, 2019

Kurt R. Karst  
Hyman, Phelps & McNamara, P.C.  
700 Thirteenth Street, NW  
Suite 1200  
Washington, DC 20005-5929

*Sent via email to:* [kkarst@hpm.com](mailto:kkarst@hpm.com)

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting to declare that the drug products Doxycycline Hyclate Tablets, 20 mg, 50 mg, 75 mg and 150 mg, are suitable for consideration in an Abbreviated New Drug Application (“ANDA”) was received by this office on 12/16/2019.

It was assigned docket number FDA-2019-P-5943. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby  
Supervisory Administrative Proceedings Officer  
Dockets Management Staff  
FDA/Office of Operations (OO)